300841 Chengdu Kanghua Biological Products
- 55.38
- -1.40-2.47%
Chengdu Kanghua Biological Products News
Chengdu Kanghua Biological Products (300841.SZ) has cumulatively repurchased 0.85% of shares, spending a total of 62.4326 million yuan.
Chengdu Kanghua Biological Products (300841.SZ) announced that as of May 31, 2024, the company has repurchased a total of 1,150,000 shares of the company through a stock repurchase dedicated securities account in the way of centralized bidding trading, accounting for 0.85% of the company's current total share capital. The highest transaction price was 63.26 yuan/share and the lowest transaction price was 45.97 yuan/share. The total transaction amount was 62,432,617.41 yuan (excluding transaction fees). The repurchase complies with the company's repurchase program and relevant laws and regulations.
Kanghua Biotech (300841): Stable performance growth in 2023, sales of human diploid wild seedlings are worth looking forward to
Incident: From March to March 2024, Kanghua Biotech disclosed the 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved operating revenue of 1,577 billion yuan, +9.03% over the same period last year; achieved net profit to mother
Kanghua Biotech (300841.SZ): Has repurchased a total of 0.85% of shares
Gelonghui, May 6, 丨 Kanghua Biotech (300841.SZ) announced that as of April 30, 2024, the company had repurchased 1,150,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.85% of the company's current total share capital. The highest transaction price was 63.26 yuan/share, the minimum transaction price was 45.97 yuan/share, and the total transaction amount was 2,6432,617.41 yuan (excluding transaction fees).
Kanghua Biotech (300841): A year-on-year improvement on the down payment cost side of receiving the Noro vaccine overseas transfer agreement
Core idea On April 23, the company released its report for the first quarter of 2024. The revenue side growth was mainly due to receiving a $15 million down payment from HillEvax. R&D expenses have dropped dramatically, leading to significant profit side growth
Kanghua Biology (300841): Noro vaccine is progressing smoothly in overseas diploid rabies vaccine continues to grow
Revenue continued to grow in 2023, and operating cash flow improved markedly. The company's 2023 revenue was 1.58 billion yuan, up 9% year on year, net profit due to mother was 510 million yuan, down 15% year on year, and net profit not returned to mother was 540 million yuan
Kanghua Biotech (300841) 2023 and 24Q1 Quarterly Report: Noro Vaccine Goes Overseas, Diploid Rabies Vaccine Continues to Grow
Revenue continued to grow in 2023, and operating cash flow improved markedly. The company's revenue in 2023 was 1.58 billion yuan, up 9% year on year, net profit due to mother was 510 million yuan, down 15% year on year, net profit after deducting non-return to mother 540 million yuan
Gao Yi's path to transfer positions came to light. Qiu Guolu, Feng Liu, and Deng Xiaofeng each reduced their holdings, and chemical and pharmaceutical stocks frequently increased their positions
① Feng Liu has continuously reduced his holdings of Hikvision, Zhongju Hi-Tech, and Baofeng Energy, and increased his holdings of pharmaceutical and chemical stocks in the first quarter; ② Deng Xiaofeng reduced his holdings of Zijin Mining, Yunlu, and China Aluminum by 3 mining stocks and has withdrawn from the top ten tradable shareholders of Wanhua Chemical; ③ Qiu Guolu also continuously reduced his holdings in the mining industry Tiandi Technology.
Kanghua Biotech (300841.SZ) plans to pay 20 yuan for 10 shares to be deducted from interest on May 8
Zhitong Finance App News, Kanghua Biotech (300841.SZ) announced that the company's 2023 equity distribution plan: a cash dividend of 20 yuan (tax included) for every 10 shares to all shareholders. The ex-dividend date is: May 8, 2024.
Kanghua Biotech (300841.SZ) announced first-quarter results, net profit of 149 million yuan, an increase of 42.09%
Kanghua Biotech (300841.SZ) released its report for the first quarter of 2024. The company's revenue was 3.11...
A number of shareholders of Kanghua Biotech (300841.SZ) completed a cumulative reduction of 718,000 shares
Kanghua Biotech (300841.SZ) announced that the company's shareholders Wu Ming, Li Wei, and Wang Qinghan have completed their holdings reduction plans,...
Kanghua Biotech (300841.SZ): A total cost of 62.43 million yuan to buy back 0.85% of shares
Gelonghui, April 1, 丨 Kanghua Biotech (300841.SZ) announced that as of March 31, 2024, the company had repurchased 1,150,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.85% of the company's current total share capital. The highest transaction price was 63.26 yuan/share, the minimum transaction price was 45.97 yuan/share, and the total transaction amount was 2,6432,617.41 yuan.
Kanghua Biotech (300841): Continued improvement in performance, significant increase in shareholder dividends
Incident: The company released its 2023 annual report. In 2023, the company achieved operating income of 1,577 million yuan, a year-on-year increase of 9.03%; net profit to mother was 509 million, a year-on-year decrease of 14.86%; net profit not attributable to mother was 5.4 million
Kanghua Biotech: Net profit in 2023 fell 14.86% year on year, and plans to pay 10 to 20 yuan
Glonghui, March 29 | Kanghua Biotech disclosed its annual report. In 2023, it achieved operating income of 1,577 million yuan, an increase of 9.03%; net profit of 509 million yuan, a year-on-year decrease of 14.86%; and basic earnings per share of 3.81 yuan. The company plans to pay a cash dividend of 20 yuan (tax included) for every 10 shares.
Kanghua Biotech (300841.SZ) received a down payment of US$15 million from HillEvax
Kanghua Biotech (300841.SZ) announced the signing of a recombinant hexavalent norovirus vaccine with HillEvax...
Express News | The first batch of fund annual reports is out! 10 billion manager's hidden heavy stock holdings revealed
A-share changes | Kanghua Biotech's market initially fell by more than 10%, actual controller Wang Zhentao filed a case
Gelonghui, March 18 | Kanghua Biotech (300841.SZ) fell more than 10% at the beginning of the market and is now reported at 60.79 yuan, with a total market value of 8.3 billion yuan. The company announced after the market last Friday that the Securities Regulatory Commission decided to file a case against the actual controller and chairman Wang Zhentao due to suspected illegal disclosure of information. According to reports, Kanghua Biotech's performance has been declining for two consecutive years.
Express News | Kanghua Biotech: Due to suspected illegal disclosure of information, the Securities Regulatory Commission decided to file a case against Chairman Wang Zhentao
Kanghua Biotech (300841): Norovirus vaccine, a leading company in human diploidy vaccine, successfully launched overseas
Report Summary Kanghua Biotech is a comprehensive vaccine company focusing on biomedical research and development. Currently, the main products sold are freeze-dried human rabies vaccine (human diploid cells) and ACYW135 meningococcal polysaccharide
Kanghua Biotech (300841.SZ): Initial repurchase of 175,000 shares involving 9.7795 million yuan
Gelonghui, February 1, 丨 Kanghua Biotech (300841.SZ) announced that on January 31, 2024, for the first time, the company repurchased 175,000 shares of the company's shares through a dedicated securities account, accounting for 0.13% of the company's current total share capital. The highest transaction price was 58.09 yuan/share, the minimum transaction price was 55.99 yuan/share, and the total transaction amount was 9.99,500 yuan (excluding transaction fees).
Express News | Kanghua Biotech: Plans to buy back the company's shares for 100 million yuan to 200 million yuan
Analysis
Price Target
No Data
